527 related articles for article (PubMed ID: 29689073)
41. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040.
McDonald SA; Azzeri A; Shabaruddin FH; Dahlui M; Tan SS; Kamarulzaman A; Mohamed R
Appl Health Econ Health Policy; 2018 Dec; 16(6):847-857. PubMed ID: 30145775
[TBL] [Abstract][Full Text] [Related]
42. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.
Chhatwal J; Chen Q; Aggarwal R
Infect Dis Clin North Am; 2018 Jun; 32(2):461-480. PubMed ID: 29778266
[TBL] [Abstract][Full Text] [Related]
43. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
Obach D; Yazdanpanah Y; Esmat G; Avihingsanon A; Dewedar S; Durier N; Attia A; Anwar WA; Cousien A; Tangkijvanich P; Eholié SP; Doss W; Mostafa A; Fontanet A; Mohamed MK; Deuffic-Burban S
Hepatology; 2015 Jul; 62(1):31-9. PubMed ID: 25581111
[TBL] [Abstract][Full Text] [Related]
44. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
45. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.
Elsharkawy A; El-Raziky M; El-Akel W; El-Saeed K; Eletreby R; Hassany M; El-Sayed MH; Kabil K; Ismail SA; El-Serafy M; Abdelaziz AO; Shaker MK; Yosry A; Doss W; El-Shazly Y; Esmat G; Waked I
J Hepatol; 2018 Apr; 68(4):691-698. PubMed ID: 29223371
[TBL] [Abstract][Full Text] [Related]
46. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
47. Securing sustainable funding for viral hepatitis elimination plans.
Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
[TBL] [Abstract][Full Text] [Related]
48. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan.
Afzal MS
Viral Immunol; 2017 May; 30(4):252-257. PubMed ID: 28118096
[TBL] [Abstract][Full Text] [Related]
50. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
51. Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study.
Jančorienė L; Rozentāle B; Tolmane I; Jēruma A; Salupere R; Buivydienė A; Valantinas J; Kupčinskas L; Šumskienė J; Čiupkevičienė E; Ambrozaitis A; Golubovska O; Moroz L; Flisiak R; Bondar B
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763696
[No Abstract] [Full Text] [Related]
52. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
53. Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan.
Zhuo Y; Hayashi T; Chen Q; Aggarwal R; Hutin Y; Chhatwal J
Sci Rep; 2020 Mar; 10(1):4089. PubMed ID: 32139872
[TBL] [Abstract][Full Text] [Related]
54. Can hepatitis C virus infection be eradicated in people who inject drugs?
Grebely J; Dore GJ
Antiviral Res; 2014 Apr; 104():62-72. PubMed ID: 24468275
[TBL] [Abstract][Full Text] [Related]
55. Urgency to treat patients with chronic hepatitis C in Asia.
Kao JH; Ahn SH; Chien RN; Cho M; Chuang WL; Jeong SH; Liu CH; Paik SW
J Gastroenterol Hepatol; 2017 May; 32(5):966-974. PubMed ID: 28005275
[TBL] [Abstract][Full Text] [Related]
56. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
Scott N; Wilson DP; Thompson AJ; Barnes E; El-Sayed M; Benzaken AS; Drummer HE; Hellard ME
BMC Med; 2019 Sep; 17(1):175. PubMed ID: 31530275
[TBL] [Abstract][Full Text] [Related]
57. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
[TBL] [Abstract][Full Text] [Related]
58. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
[TBL] [Abstract][Full Text] [Related]
59. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016.
Nasrullah M; Sergeenko D; Gvinjilia L; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Alkhazashvili M; Shadaker S; Ward JW; Morgan J; Averhoff F
MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(29):773-776. PubMed ID: 28749925
[TBL] [Abstract][Full Text] [Related]
60. Global burden of hepatitis C: considerations for healthcare providers in the United States.
Averhoff FM; Glass N; Holtzman D
Clin Infect Dis; 2012 Jul; 55 Suppl 1():S10-5. PubMed ID: 22715208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
